首页> 外文期刊>BMC Cardiovascular Disorders >Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care
【24h】

Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care

机译:稳定冠心病和继发性心血管疾病事件风险患者的细胞色素P450 2C19 * 2基因多态性:常规临床护理中长期随访研究的结果

获取原文
           

摘要

Background CYP2C19*2 polymorphism is related to metabolizer phenotypes resulting in reduced effectiveness in converting the antiplatelet drug clopidogrel to active drug. An association of the genotype itself with adverse outcomes is discussed. We investigated the prognostic value of carriage of the CYP2C19*2 allele in a high risk group of patients with prevalent coronary heart disease (CHD) at baseline during long-term follow-up under conditions of routine clinical care. Methods In n=1050 patients with stable CHD at baseline genotyping of CYP2C19 allele *2 (rs4244285; 681G>A) was performed. The Cox-proportional hazards model was employed to investigate the association of CYPC19*2 allele status with cardiovascular disease (CVD) events during eight year follow-up. The analysis was also performed in patients who did not take clopidogrel or ticlopidin. Results Only the very few patients homozygous for a loss-of-function variant of CYP2C19, allele *2 (2.6%), had a statistically significantly higher incidence rate for secondary CVD events during long-term follow-up than wild-type carriers (50.8 versus 21.5 per 1000 patients years; rate for heterozygous carries 17.2 per 1000 patient years). The hazard ratio after adjustment for covariates compared to the wild-type carriers was 2.59 (95% confidence interval (CI) 1.27-5.28) and 0.80 (95% CI 0.52-1.23) for homozygous and heterozygous allele carriers, respectively. Conclusions In this medium-size group of patients with stable CHD homozygous carriers of the loss-of-function allele CYP2C19*2 were at increased risk for subsequent CVD events during 8 year follow-up independent of other risk factors. As only few patients carried the homozygous loss-of-function variant and we found overall no evidence for improved clinical utility, a benefit of genotyping in this patient population seems unlikely.
机译:背景CYP2C19 * 2多态性与代谢物表型有关,导致将抗血小板药物氯吡格雷转换为活性药物的有效性降低。讨论了基因型本身与不良结局的关联。我们在常规临床护理条件下的长期随访期间,研究了CYP2C19 * 2等位基因在基线高危人群中的临床应用价值。方法在n = 1050名稳定的CHD患者中,对CYP2C19等位基因* 2(rs4244285; 681G> A)进行基线基因分型。使用Cox比例风险模型调查CYP19 * 2等位基因状态与八年随访期间的心血管疾病(CVD)事件的相关性。还对未服用氯吡格雷或ticlopidin的患者进行了分析。结果CYP2C19功能丧失的纯合子等位基因* 2(2.6%)只有极少数的患者在长期随访期间发生继发性CVD事件的发生率在统计学上显着高于野生型携带者(每1000病人年50.8比21.5;每1000病人年杂合率17.2)。与野生型携带者相比,对协变量进行调整后的风险比分别为纯合和杂合等位基因携带者为2.59(95%置信区间(CI)1.27-5.28)和0.80(95%CI 0.52-1.23)。结论在此中等规模的患者中,功能稳定的等位基因CYP2C19 * 2的稳定CHD纯合子携带者在随后的8年随访中发生CVD的风险增加,而与其他危险因素无关。由于只有少数患者携带纯合子功能丧失变异体,并且我们总体上未发现改善临床效用的证据,因此在这种患者群体中进行基因分型的益处似乎不太可能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号